Having trouble viewing this email? View it online here
Drug Discovery Today
Enhancing productivity and accuracy in drug metabolism studies with the latest Orbitrap technology
          WEBSITE           MAGAZINE REGISTRATION           EVENTS           CONTACTS                                                                     RSS   RSS feed

Drug Discovery Today News - 1 Dec 2011

Editor's Choice

Critical considerations for your ‘biomarker’ strategy Biomarkers. There was a time in the not-so-distant past when simply identifying a biomarker was considered a drug discovery success. Like the low hanging fruit initially exposed by the genomic revolution, that once common view has long since disappeared. Today, the line between the bench and the clinic is becoming increasingly blurred. Translational science has become a core element of the drug discovery paradigm, and with it has come an increasing need for an integrated, multidisciplinary approach to biomarker development. More
Drug Discovery: a job too complex for academia or industry alone?

Key Research Articles

World’s first stem cell bandage in human clinical trials The company behind a pioneering stem cell bandage, believed to be the world’s first adult and autologous (patient’s own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK’s most successful entrepreneurs. More

Drug Delivery: Enabling Technology for Discovery and Development

Pantarhei Bioscience announces discovery of antigen (ZP3) as a treatment to combat ovarian cancer Pantarhei Bioscience, a specialty pharmaceutical company focusing on the development of innovative, proprietary treatments in the fields of women’s health and endocrine cancer, announces the publication in the Journal of the Federation of American Societies for Experimental Biology (FASEB J October 5, 2011) of the results of an innovative treatment strategy for ovarian cancer, which has now been selected to appear in the Faculty of 1000 (F1000) emphasizing its significance. More

Drug Discovery Today

New approach to benefit-risk offers informed, tailored decision-making for non-prescription medicines As consumers and health systems move toward greater reliance on self-care, regulatory and clinical decision making should be improved through new tools to assess the unique benefits and challenges of self-care nonprescription [‘over-the-counter’, (OTC)] products, according to a new White Paper published in the peer-reviewed journal Clinical Pharmacology & Therapeutics. More

Almac publishes Stage II colon cancer recurrence signature in the Journal of Clinical Oncology Almac’s Diagnostics business unit today announced the publication of its stage II colon cancer recurrence signature (diagnostic test) in the Journal of Clinical Oncology. More

Downloads/ White Papers

The biomarker is not the end
23 November 2011
In this article Michael Nohaile discusses several areas of expertise that need to be considered for drug discovery and translational scientists to use stratification with biomarkers to improve the chances of getting medicines to patients.
More

Clinical and biological data integration for biomarker discovery
23 November 2011
Sorani et al. describe a data integration strategy that implements a clinical and biological database and a wiki interface. They integrated parameters across clinical trials and associated genetic, gene expression and protein data. They also provide examples to illustrate the utility of data integration to explore disease heterogeneity and develop predictive biomarkers.
More

Recent progress toward biomarker identification in osteoarthritis
23 November 2011
In this review, De Ceuninck et al. highlight the difficulties associated with osteoarthritis diagnosis and discuss the most recent research efforts and successes for the identification of reliable osteoarthritis biomarkers.
More

A generic operational strategy to qualify translational safety biomarkers
23 November 2011
The importance of using translational safety biomarkers that can predict, detect and monitor drug-induced toxicity during human trials is becoming increasingly recognized. In this article Matheis et al. discuss a generic qualification strategy, established by the IMI SAFE-T consortium, for new translational safety biomarkers that will allow early identification, assessment and management of drug-induced injuries throughout R&D.
More

For a full list of downloads/ white papers, please visit
http://www.drugdiscoverytoday.com/downloads/

Events

Dissolution testing for the pharmaceutical industry
Dates: 12 December 2011 until 14 December 2011
Location: The Moller Centre, Cambridge, UK
Website: http://www.europabio.org/healthcare/events/dissolution-testi...
More

Drug discovery: a job too complex for academia or industry alone?
Dates: 05 January 2012 until 06 January 2012
Location: Medical Sciences Teaching Centre - University of Oxford, UK
Website: http://www.thesgc.org/events/symposia/DrugDiscov2012
More

Novel Immunotherapeutics Summit
Dates: 30 January 2012 until 31 January 2012
Location: Paradise Point Resort & Spa, 1404 Vacation Road, San Diego, CA, USA
Website: http://www.gtcbio.com/index.php?option=com_conference&file=h...
More

10th Cytokines and Inflammation Conference
Dates: 30 January 2012 until 31 January 2012
Location: Paradise Point Resort & Spa, San Diego, CA, USA
Website: http://www.gtcbio.com/index.php?option=com_conference&file=h...
More

For a full list of events and conferences, please visit
http://www.drugdiscoverytoday.com/events/

Received this from a colleague? Sign up for your own regular copy of Drug Discovery Today Weekly.

This e-mail has been sent to you from Elsevier, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, registered in England with registered number 1982084.

You are receiving this e-mail because you are a registered subscriber of Drug Discovery Today. We respect your privacy and do not rent, sell or disclose your personal information to any non-affiliated third party without your consent, except as may be stated in our site's Privacy Policy: http://www.drugdiscoverytoday.com/legal/privacy/